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Abstract
Background: The development of multi-drug resistant (MDR) cancer is a significant challenge in the clinical
treatment of recurrent disease. Hypoxia is an environmental selection pressure that contributes to the development
of MDR. Many cancer cells, including MDR cells, resort to glycolysis for energy acquisition. This study aimed to
explore the relationship between hypoxia, glycolysis, and MDR in a panel of human breast and ovarian cancer cells.
A second aim of this study was to develop an orthotopic animal model of MDR breast cancer.
Methods: Nucleic and basal protein was extracted from a panel of human breast and ovarian cancer cells; MDR
cells and cells pre-exposed to either normoxic or hypoxic conditions. Western blotting was used to assess the
expression of MDR markers, hypoxia inducible factors, and glycolytic proteins. Tumor xenografts were established in
the mammary fat pad of nu/nu mice using human breast cancer cells that were pre-exposed to either hypoxic or
normoxic conditions. Immunohistochemistry was used to assess the MDR character of excised tumors.
Results: Hypoxia induces MDR and glycolysis in vitro, but the cellular response is cell-line specific and duration
dependent. Using hypoxic, triple-negative breast cancer cells to establish 100 mm3 tumor xenografts in nude mice
is a relevant model for MDR breast cancer.
Conclusion: Hypoxic pre-conditiong and xenografting may be used to develop a multitude of orthotopic models
for MDR cancer aiding in the study and treatment of the disease.
1. Introduction
1.1. Multi-Drug Resistance in Cancer
The development of multi-drug resistant (MDR) cancer
is a challenge in the treatment of non-responsive, recur-
rent disease [1-6]. MDR refers to a state of resilience
against structurally and/or functionally unrelated drugs;
MDR can be intrinsic (innate) or acquired through
exposure to chemotherapeutic agents [1].
The mechanisms of MDR include decreasing drug
influx into a cell, increasing drug efflux out of a cell,
increased DNA repair, increased drug metabolism/
detoxification, and decreased apoptosis [7]. The most
characterized mechanism of MDR is increased drug
efflux through transmembrane pumps [7-9]. Over 13
ATP-Binding Cassette (ABC) transporters have been
verified to contribute to MDR; of these, P-glycoprotein
(Pgp) is the most consistently over-expressed and the
most studied ABC transporter involved in the develop-
ment of MDR cancer [8-10]. Membrane-bound Pgp
effluxes a broad spectrum of substrates and active efflux
requires the hydrolysis of two ATP molecules [7].
A recent study evaluating the cellular onset of MDR iden-
tified Pgp over-expression as the primary mechanism of
MDR before malignant transformation [6]. Pgp over-
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expression is associated with poor prognosis in many types
of cancer [7]. Other ABC transporters that contribute to
MDR include multi-drug resistance protein 1 (MRP-1,
ABCC1) and breast cancer resistance protein (BCRP,
ABCG2) [9-12]. Additional proteins, such as growth factor
receptors, are also used as markers of MDR; for example,
over-expression of epidermal growth factor receptor
(EGFR) is often associated with aggressive phenotypes and
is used as a MDR marker in certain types of cancer
[13-15].
1.2. Hypoxia and the Tumor Microenvironment
Perhaps the most significant contributor that defines the
microenvironment of a tumor is the tumor vasculature
[16-18]. The vascular network provides a tumor with
oxygen and nutrients and is an avenue for the tumor to
metastasize to remote sites. The importance of tumor
vasculature is exploited by the plethora of anti-vascula-
ture and anti-angiogenic cancer therapies [19,20]. Yet
this vasculature is highly disorganized and constantly
changing. Angiogenesis and vascular destruction are
dynamic, ongoing processes; as the tumor is established
new blood vessels are formed, this process continues as
the tumor grows, but as the tumor propagates and
expands blood vessels may be destroyed or cut off
[16-18]. This haphazard process of neo- and de-vascu-
larization contributes to the evolving phenotype of a
tumor. A critical consequence of this fluctuation is a
corresponding fluctuation in oxygen and glucose levels
which results in heterogeneous states of hypoxia, anae-
robic glycolysis (the Pasteur effect), and aerobic glycoly-
sis (the Warburg effect) [17].
States of chronic hypoxia and transient hypoxia may
occur and alter within the same tumor mass [21].
Chronic hypoxia occurs when a cell is beyond the diffu-
sion limit of oxygen from a blood vessel (70-100 μm)
whereas transient hypoxia occurs due to local oxygen
depletion [21].
The cascade of proteome alterations that occurs in
response to hypoxia begins with the transcription factor,
Hypoxia Inducible Factor (HIF). HIF consists of alpha
and beta subunits [22,23]. HIF-1a and HIF-1b are the
most common isoforms; expression of HIF-2a and HIF-
3a is more limited to healthy (non-cancerous) tissue [23].
Synthesis of the alpha subunit is oxygen independent
while degradation is oxygen dependent [22,24]. Under
conditions of hypoxia, the alpha subunit of HIF is stabi-
lized and is then able to translocate to the nucleus
[22,24,25]. Once localized to the nucleus, HIF-a forms a
complex with HIF-b; this activated HIF complex is then
able to bind to hypoxia responsive elements (HRE) on
target genes inducing transcription [22,24].
Hypoxia has been shown to contribute to MDR and
resistance to radiation therapy [17,21,24,26-29]. Some of
the HIF-1a targets involved in MDR and aggressive can-
cer involve MDR1, matrix metalloproteinases (MMP),
vascular endothelial growth factor (VEGF), VEGF recep-
tor, transforming growth factor (TGF)-a, cyclooxygenase
(COX)-2, nitric oxide synthase (NOS), insulin-like
growth factor (IGF)-2, cathepsin D (CATHD), collagen
type V (a1) [21,22,24,26,28-32]. HIF-1a also targets gly-
colytic proteins such as the glucose transporters GLUT-1
and GLUT-3, hexokinase 1 and 2, phosphofructokinase
(PFK), aldolase, glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), phosphoglycerate kinase (PGK), enolase,
pyruvate kinase, and lactate dehydrogenase (LDH)
[21,22,24,26,28,29,32-36]. Reverse activation: glycolytic
proteins activating HIF-1a, has also been demonstrated.
This implies a possible feedback loop between the glyco-
lytic and HIF-1a pathways that may be critical in the
transformation of a normal cell into a cancer cell [34].
HIF is stabilized under hypoxia but also by many oxy-
gen-independent factors such as epidermal growth
factor receptor (EGFR), heat-shock protein 90, phospha-
tidylinositol 3-kinase, and cyclooxygenase-2 activity
[24,37,38]. As such, HIF has been established to contri-
bute to cancer cell glycolysis in both the absence and
presence of oxygen (the Pasteur and Warburg Effects)
[34,35,39-41].
1.3. The Pasteur and Warburg Effects
Traditionally, in the presence of oxygen cells obtain
energy through oxidative phosphorylation (OXPHOS)
and oxygen inhibits glycolysis; this inhibition is known
as the Pasteur effect [39]. Some cancer cells also
undergo aerobic glycolysis (the Warburg effect); this
phenomenon was first discovered by Otto Warburg in
1930 [39,42-45]. As there is a constant flux in the oxy-
genation states of a solid tumor (between normoxic,
hypoxic, and anoxic levels), increased glycolysis in both
the absence and presence of oxygen are important hall-
marks of cancer [34,35,39-41].
The biological motivation for increased glycolysis is
multifold. First, glycolysis is much safer than oxidative
phosphorylation. OXPHOS produces ROS which can be
very damaging to the delicate balance of ROS main-
tained in an abnormal cancer cell; decreasing reliance
on OXPHOS is a means of limiting ROS accumulation
[39,46]. Secondly, although the net energy yield from
glycolysis is much lower than OXPHOS (2 ATP verses
36), the process is much faster, providing a cell with
direct energy acquired in the cytoplasm [39]. Third, a
decreased reliance on OXPHOS ensures that oxygen
does not become a limiting factor to survival [39,47].
Fourth, the glycolytic pathway provides precursors for
biomolecules necessary for proliferation [39,47]. Fifth,
this increased glycolytic character may provide tumor
protection and enhance invasion; the low pH resulting
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from lactic acid accumulation may sensitize normal cells
to invasion while protecting the tumor from the
immune system [39,47]. Synergistically, these biological
motivations for increasing glycolysis provide a survival
advantage for a cancer cell.
As noted above, many glycolytic proteins are HIF tar-
gets, HIF is activated by many factors independent of
oxygen levels, and HIF has been established to contri-
bute to both the Pasteur and Warburg effects. Due to
the fluctuating oxygenation states within a tumor it is
possible that hypoxia induced glycolysis (the Pasteur
effect) may pre-condition cancer cells for aerobic glyco-
lysis (the Warburg effect).
As demonstrated by the schema in Figure 1, the first
aim of the current study was to explore the relationship
between hypoxia, MDR, and glycolysis in a panel of
breast and ovarian cancer cell lines (top half of Figure 1).
This was done by exposing the panel of cells to normoxic
and hypoxic conditions, extracting the nucleic and basal
protein, and examining protein expression through wes-
tern blotting. Proteins included markers of MDR (Pgp
and EGFR), markers of hypoxia (HIF-1a), and glycolytic
markers (GLUT1 and HXK2); additional protein markers
were also examined. Also demonstrated by the schema in
Figure 1, the second aim of this study was to compare
the protein expression of MDR, hypoxic, and glycolytic
markers in tumor xenografts established from cells pre-
exposed to normoxic conditions and from xenografts
established from cells pre-exposed to hypoxic conditions
(bottom portion of Figure 1). This was done through
immunohistochemistry of the excised tumors. Within the
two xenograft groups (normoxic pre-exposure and
hypoxic pre-exposure), tumors of three different sizes
were examined (100 mm3, 250 mm3, and 500 mm3). This
study resulted in the establishment of an orthotopic
model for MDR breast cancer.
2. Materials and methods
2.1. Cell Culture and Hypoxia
For this study, a panel of ovarian and breast cancer cell
lines were selected. An established MDR ovarian cancer
cell line, SKOV3TR cells, were used as a positive control
for MDR protein character. Corresponding wild-type
and hypoxic SKOV3 cells were also used. MDA-MB-231
breast cancer cells, were selected for their aggressive
character. These cells are triple negative (negative for
estrogen receptors, progesterone receptors, and HER2;
human epidermal growth factor receptor 2). Triple
negative breast cancer is known to be one of the most
aggressive, recurrent multiforms of breast cancer.
Another ovarian cancer cell line, OVCAR5 cells, were
selected as a less aggressive comparison to the other cell
types. MDA-MB-435 cells were selected as a negative
control for EGFR expression.
SKOV3 cells, MDA-MB-231 cells, and OVCAR5 cells
were obtained from ATCC (Manassas, VA). The
SKOV3TR cells and the MDA-MB-435 cells were a kind
gift from Dr. Duan (Massachusetts General Hospital,
Sarcoma Molecular Biology Laboratory). Cells were pla-
ted at very low density and incubated at 37°C and main-
tained in RPMI-1640 media (Mediatech, Inc; Manassas,
VA) supplemented with 10% fetal bovine serum (Gemini
Bio-products; West Sacramento, CA) and 1% penicillin/
streptomycin/amphotericin B mixture (Lonza; Walkers-
ville, MD). To create hypoxic conditions using low-
oxygen gas; cell culture flasks were placed in a modular
incubation chamber (Billups-Rothenberg, Inc.; Del Mar,
CA), flushed with a 0.5% O2, 5% CO2, nitrogen balanced
gas for five minutes, and incubated at 37°C for various
time points. As per manufacturer recommendations, the
chamber was filled at a rate of 20 liters/minute for five
minutes for complete saturation.
2.2. Protein Extraction and Western Blot Analysis
Basal and nucleic protein fractions were extracted from
cells grown to 90% confluency in 75 cm2 tissue culture
flasks under normoxic and hypoxic conditions. Before
extraction, cells were microscopically examined to con-
firm cell viability and the absence of excessive cell
death. Basal protein was extracted using a high salt lysis
buffer at 4°C. Nucleic protein was obtained using the
NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce
Biotechnology; Rockford, IL). Protein concentrations
were quantified using the BCA Protein Assay (Pierce
Biotechnology). Protein was separated on 4-20% gradi-
ent SDS-PAGE gels (PAGEgel, Inc.; San Diego, CA) and
transferred onto PVDF membranes (0.45 μm pore; Milli-
pore, Billerica, MA). Membranes were blocked for
30 minutes with StartingBlock™ buffer (Pierce Biotech-
nology) before an overnight incubation with the primary
antibody at 4°C. Membranes were then washed with
TBST for 10 minutes (three times) and subsequently
incubated with a horseradish peroxidase conjugated sec-
ondary antibody for 1 hour. Membranes were again
washed with TBST, flash rinsed with deionized distilled
water, incubated for 2-10 minutes in an enhanced che-
miluminescence substrate (Pierce Biotechnology), and
imaged using a Kodak FX Imaging Station (Rochester,
NY). All blocking and washing steps were conducted at
room temperature. P-glycoprotein antibody was pur-
chased from Calbiochem while the EGFR antibody was
purchased from Cell Signaling Technology (Danvers,
MA). The remaining primary and secondary antibodies
were purchased from Abcam (Cambridge, MA).
2.3. Protein Quantification
Semi-quantitative analysis was performed on the wes-
tern blot data presented in Figure 2. To this end, Image
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Figure 1 Experimental Schema. The primary aim of the current study was the development of an orthotopic model of multidrug resistant
(MDR) breast cancer. To achieve that aim we conducted a study with two phases, in vitro and in vivo, as portrayed by the top and bottom
portions of the figure. The first phase of the study consisted of exposing a panel of human cancer cells to either normoxic or hypoxic conditions
and measuring the expression of protein markers for MDR, hypoxia, and glycolysis. These markers are portrayed by the cell diagram in the top,
middle segment of the figure. The second phase of the study entailed selecting one cell line, exposing the human breast cancer cells to either
normoxic or hypoxic conditions for five days, and then xenografting these cells into the mammary fat pad of nude mice. After tumors grew to
100 mm3, 250 mm3, and 500 mm3, they were excised and immunohistochemistry (IHC) was used to assess the expression of MDR, hypoxic, and
glycolytic markers. Hypoxic pre-conditioning of xenografted cells did result in tumors with more MDR character than tumors established from
normoxic cells. EGFR, epidermal growth factor receptor; HIF, hypoxia inducible factor; HXK2, hexokinase 2; Pgp, P-glycoprotein; GLUT1, glucose
transporter 1.
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Figure 2 Protein Expression Analysis. Nucleic protein (A) and basal protein (B) were extracted from the panel of cell lines grown under
normoxic (wild-type; WT) and hypoxic conditions (three and five days of hypoxia; 3-day Hyp and 5-day Hyp). The nuclear protein was probed
for expression of the hypoxia inducible transcription factors HIF-1a and HIF-2a (TATA-binding protein was used as a nuclear loading control).
Basal protein was probed for expression of MDR markers (P-glycoprotein, Pgp; multidrug resistance protein 1, MRP1), EGFR, glycolytic proteins
(GLUT-1 glucose transporter; Hexokinase 2, HXK2; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; lactate dehydrogenase, LDH), and
mitochondrial ATP synthase. b-actin was used as a loading control for basal protein.
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J software was used; the integrated density of each band
was measured, this value was divided by the integrated
density of the control band to determine the relative
intensity. The control band for nucleic protein expres-
sion was TATA-binding protein while the control band
for basal protein expression was b-actin.
2.4. Animals and Orthotopic Model Development
Female nu/nu mice were procured from Charles River
Laboratories (Wilmington, MA) and were housed in
sterile cages on a 12:12 light/dark cycle with ad libitum
acess to food and water. All procedures were approved
by the Northeastern University Animal Care and Use
Committee.
A total of 36 mice were used for this study; 18
received tumor cells pre-exposed to normoxic condi-
tions for five days and 18 received tumor cells pre-
exposed to hypoxic conditions for five days. Each group
(normoxic and hypoxic) was further dived into three
subgroups of 6 mice based on tumor size (100 mm3,
250 mm3, and 500 mm3).
To establish the xenografts, approximately 2 million
human breast cancer cells (normal MDA-MB-231 or
hypoxic MDA-MB-231 cells) suspended in a 100 μl of a
50:50 mix of matrigel and serum free medium was
injected into the mammary fat pad of the mice while
they were under light isoflurane anesthesia. Pre-chilled,
sterile syringes with 27 gauge, ½’’ needles were used to
inject the tumor cells. Syringes were pre-chilled at 4°C
to prevent coagulation and immediate gelling of the
matrigel.
The tumor size was measured every other day using
Vernier calipers in two dimensions. Individual tumor
volumes were calculated using the formula volume =
[length × (width)2]/2 where length is the longest dia-
meter and width is the shortest diameter perpendicular
to length. Tumors were allowed to grow to the allocated
volumes of 100 mm3, 250 mm3, and 500 mm3. During
this time, animals were monitored every alternate day
for body weight, eating/drinking behavior, and general
health. Once tumors reached the desired size, the mice
were euthanized via carbon dioxide inhalation. Tumors
were then excised.
2.5. Immunohistochemistry of Tumors
Excised tumors were embedded in section medium
(Richard-Allan Neg 50*, Thermo Scientific, Waltham,
MA), flash frozen in liquid nitrogen, and stored at -80°C
until use. Embedded tumors were thawed to -20°C,
cryo-sectioned into 7 μm thick sections, and mounted
onto glass slides (SuperFrost Plus®, Thermo Scientific,
Waltham, MA). Sections were outlined with an Aqua
Hold Pap Pen (Scientific Device Laboratory, Des Plaines,
IL), air dried at room temperature, then stored at -20°C.
Sections were then thawed to room temperature and
fixed in ice-cold acetone for 10 minutes. Sections were
air dried at room temperature for 1 hour, and rinsed in
two changes of cold PBS (5 minutes each). Then sec-
tions were incubated with 100 μl of IHC Select® Block-
ing Reagent (Chemicon, Billerica, MA) in a humidified
chamber at 37°C for 30 minutes. The blocking buffer
was then drained off, the slides rinsed in PBS, and then
each section was incubated with 100 μl of primary anti-
body diluted in IHC Select® Antibody Diluent Solution
(Chemicon, Billerica, MA), overnight at 4°C. Slides were
rinsed in two changes of PBST and each section was
incubated with 100 μl of secondary antibody diluted in
IHC Select® Antibody Diluent Solution (Chemicon, Bill-
erica, MA), at room temperature for 30 minutes. Slides
were washed in two changes of PBS and incubated with
a solution of Alexa Fluor® 568 phalloidin (to stain
F-actin) and Hoechst 33342 (to stain nuclei) (Invitrogen;
Carlsbad, CA) for 20 minutes. Slides were rinsed in
PBST and dehydrated in 95% ethanol for 2 minutes, and
100% ethanol for two exchanges (3 minutes each).
Tissue sections were then immersed with Prolong
Gold® Antifade reagent (Invitrogen; Carlsbad, CA), cov-
ered with glass cover slips, and allowed to cure over-
night at room temperature. All primary antibodies were
from Cell Signaling Technology (Danvers, MA), except
for the GLUT-1 antibody which was from Abcam (Cam-
bridge, MA). The secondary antibodies were Alexa
Fluor® 488 goat anti-mouse IgG (H + L) and Alexa
Fluor® 488 goat anti-rabbit IgG (H + L) (Invitrogen;
Carlsbad, CA). Slides were imaged using an Olympus
IX51 Microscope.
3. Results
3.1. Protein Analysis of Hypoxic, MDR, and Glycolytic
Markers
The panel of cell lines (detailed in the materials and
methods) were exposed to hypoxic conditions (0.5%
oxygen) for three and five days. The basal protein and
nucleic protein from cells exposed to hypoxic and nor-
moxic conditions was extracted and western blotting
was used to analyze the expression of hypoxic factors,
MDR markers, and downstream proteins induced under
hypoxic regulation.
Nuclear protein analysis (Figure 2A) revealed that
HIF-1a expression was apparent in all cells but was ele-
vated in the MDR cells (lane 2), in cells exposed to
hypoxic conditions for 3 days (lanes 3, 6, and 9), and in
cells exposed to hypoxic conditions for 5 days (lanes 4,
7 and 10). Interestingly, in the SKOV3 cell line (lane 3)
and in the OVCAR5 cell line (lane 9), 3-days of hypoxia
was not substantial in inducing HIF-2a nuclear translo-
cation (Figure 2A). Yet, in the MDA-MB-231 breast
cancer cells (lane 6), 3 days of hypoxia did induce
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nuclear translocation of HIF-2a. Five days of hypoxic
exposure resulted in nuclear accumulation of HIF-2a in
all three cell lines (lane 4, 7, and 10). Also of signifi-
cance, HIF-2a nuclear translocation was not evident in
the MDR cells.
Markers of MDR were also examined in the three cell
lines under normoxic and hypoxic conditions (Figure
2B). The high expression of Pgp in the MDR cells is evi-
dent (lane 2). Three days of hypoxic exposure was not
sufficient to induce Pgp expression in the SKOV3 cells
(lane 3) or to increase Pgp expression in the MDA-MB-
231 cells (lane 6, which appears the same as the basal
level in lane 5). Five days of hypoxia, however, was suffi-
cient in inducing Pgp expression in both the SKOV3
ovarian cancer cells (lane 4) and in the MDA-MB-231
breast cancer cells (lane 7). The OVCAR5 ovarian can-
cer cells appear more resistant to Pgp induction as there
is only a faint band of protein after five days of hypoxic
exposure (lane 10). The only wild type cancer cell line
that expresses a basal level of Pgp under normoxic con-
ditions is the MDA-MB-231 breast cancer cell line (lane 5).
MRP-1 (multi-drug resistance protein 1) is also an ABC
transporter involved in drug efflux. The MRP-1 expres-
sion profile was similar to the expression of Pgp in the
cell lines examined. The only significant difference in
MRP-1 expression is that 3 days of hypoxic exposure
was sufficient in increasing MRP-1 expression in the
MDA-MB-231 cells (lane 6) while five days of hypoxia
did not even induce faint expression in the OVCAR5
cells (lane 10).
Although over-expression of growth factors is charac-
teristic of cancer cells in general, this over-expression is
a particularly vital survival mechanism for hypoxic MDR
tumor cells as these cells are often distal from a con-
stant supply of nutrients and growth factors; hypersensi-
tivity to these factors increases the propensity for
growth and maintenance. As expected, EGFR expression
was elevated in MDR cells (lane 2) relative to wild type
SKOV3 cells maintained under normoxic conditions
(lane 1) (Figure 2B). Three days of hypoxic exposure did
not substantially increase EGFR expression in SKOV3
cells (lane 3), yet five days of hypoxic exposure resulted
in a more pronounced expression level (lane 4). For the
MDA-MB-231 breast cancer cells, there was a marked
increase in EGFR expression after both 3 and 5 days of
hypoxic exposure. The high basal level of EGFR expres-
sion in OVCAR5 cells grown under normoxic condi-
tions (lane 8) was maintained after 3 days of hypoxia
(lane 9) and elevated after 5 days of hypoxia (lane 10).
Wild type MDA-MB-435 cells grown under normoxic
conditions do not express notable levels of EGFR
(lane 11). As with other HIF-1a targets, the level of EGFR
induction seems to be cell type dependent and related to a
threshold of hypoxic exposure. TATA-binding protein was
used as a loading control for nucleic protein (Figure 2A)
and b-actin was used as a loading control for basal protein
(Figure 2B).
To examine the relationship between hypoxia, MDR,
and glycolysis the protein expression of four glycolytic
proteins that are transcriptionally activated by HIF-1a
were analyzed in the panel of cells; GLUT-1 glucose
transporter, Hexokinase 2 (HXK2), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and lactate dehy-
drogenase (LDH) (Figure 2B).
GLUT-1 glucose transporter is significant to MDR
hypoxic cell survival in much the same way as EGFR.
These cells that are located in poorly or non-
vascularized regions are starved for nutrients and
increase their prospects of survival by increasing the
expression of nutrient importers such as GLUT-1. As
demonstrated in Figure 2B, MDR cells (lane 2) have an
elevated level of GLUT-1 expression relative to wild
type SKOV3 cells grown under normoxic conditions
(lane 1). Three days of hypoxia was not sufficient in ele-
vating this expression in SKOV3 cells (lane 3) and
OVCAR5 cells (lane 9), but elevation was evident after
five days of hypoxia (lane 4 and lane 10). Conversely,
three days of hypoxia appeared to slightly increase
GLUT-1 in MDA-MB-231 cells (lane 6) while five days
of hypoxia further increased this expression (lane 7).
The expression of hexokinase 2 (the enzyme that cata-
lyzes the first step of glycolysis) was similar to the
expression of GAPDH (an intermediate glycolytic
enzyme) and LDH (the terminal glycolytic enzyme) (Fig-
ure 2B). For these three proteins, there was only a
slightly higher expression level in the MDR cells (lane 2)
relative to normoxic SKOV3 cells (lane 1) while
increased hypoxic exposure lead to an increase in pro-
tein expression in the SKOV3 cell line and the MDA-
MB-231 cell line. The OVCAR5 cells appeared to have a
low basal level of HXK2, GAPDH, and LDH that did
not appear to be induced by hypoxia (lanes 8, 9, and 10).
Conversely, the MDA-MB-435 wild type cells grown
under normoxic conditions express high basal levels of
HXK2, GAPDH, and LDH (lane 11).
Interestingly, expression of mitochondrial ATP
synthase, the ATP producing component of OXPHOS
coupled to the electron transport chain, did not corre-
late with hypoxic exposure across the cell lines. There
was no difference in expression between the MDR cells
and the normoxic SKOV3 cells while five days of
hypoxia decreased expression in this cell line. Five days
of hypoxia also decreased expression in the OVCAR5
cell line. On the other hand, hypoxia (three and five
days) increased the expression of ATP synthase in the
MDA-MB-231 cell line.
Semi-quantitative analysis was performed on the
western blot data presented in Figure 2. The results of
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this analysis are presented in Figure 3, Figure 4, and
Figure 5. The semi-quantitative analysis is consistent
with the interpretations of the western blot data;
hypoxic exposure appears to increase the expression of
HIF-1a, HIF-2a, Pgp, MRP-1, EGFR, and the glycolytic
proteins in the SKOV3 and MDA-MB-231 cells yet the
OVCAR5 cells appear to be resistant to hypoxia induced
MDR and hypoxia induced glycolysis.
3.2. Development and Characterization of MDR Tumor
Xenografts
The MDA-MB-231 cells were selected for hypoxic pre-
conditioning and tumor xenografting as these cells
demonstrated the most notable response to hypoxia in
the in vitro studies; hypoxia substantially increased the
expression of MDR markers and glycolytic proteins rela-
tive to the expression in normoxic cells. A total of 36
mice were used for this study; 18 mice were injected
with MDA-MB-231 cells grown under normoxic condi-
tions while 18 were injected with MDA-MB-231 cells
pre-exposed to hypoxic conditions. The cells were
injected in the mammary fat pad of the mice for the
development of orthotopic tumors. Tumors were grown
to three sizes; 100 mm3, 250 mm3, and 500 mm3. The
objectives of this study was to determine which group
resulted in tumors with the most MDR character by
assessing (1) if there was a difference between tumors
developed from cells grown under normoxic conditions
and tumors developed from cells pre-exposed to hypoxic
conditions, (2) if there was a difference between tumors
of different sizes. To determine such differences
between the groups, 6 proteins were selected for tissue
immunohistochemistry; Pgp, CD-31, HIF-1a, EGFR,
HXK2, and GLUT-1. Tumors were sectioned into 7 uM
slices, F-actin was labeled with Alexa Fluor® 568
phalloidin (red), nuclei were stained with Hoechst 33342
(blue), and the sections were probed for the protein of
interest using primary antibodies against the protein and
Alexa Fluor® 488 conjugated secondary antibodies
(green).
The 100 mm3 tumors are illustrated in Figure 6, the
250 mm3 tumors are illustrated in Figure 7, and the
500 mm3 tumors are illustrated in Figure 8. Figures 6, 7,
&8 depict IHC of tumor cores representative of n = 6
for each group. There were demonstrated differences in
the protein expression profiles of 100 mm3 tumors
developed from cells grown under normoxic conditions
and from tumors developed from cells pre-exposed to
hypoxic conditions. There was minimal and localized
expression of Pgp in the tumors developed from nor-
moxic cells whereas there was profuse expression of Pgp
in the tumors developed from hypoxic cells. There was
no apparent difference in CD-31 expression; this marker
was used to assess angiogenesis. Again, there was loca-
lized and minimal expression of HIF-1a in the tumors
developed from cells grown under normoxic conditions
whereas there was profuse expression in the tumors
derived from hypoxic cells; this expression appeared to
be localized with both the cytoplasmic and nucleic frac-
tions of the cells. Both groups of tumors had high levels
of EGFR. Expression of hexokinase 2 and GLUT-1 was
minimal and localized in the tumors derived from nor-
moxic cells and profuse in the tumors derived from
hypoxic cells.
These expression trends continued in the 250 mm3
tumors (Figure 7), although there was less of a differ-
ence as the tumors developed from normoxic cells seem
to express higher levels of these marker proteins in
tumors of this size. Excessive expression of all marker
proteins (except CD-31) was apparent in both groups of
Figure 3 Semi-quantitative Analysis of HIF-1a and HIF-2a. Image J software was used to determine the relative intensity of protein
expression. The integrated density of each band was measured; this value was divided by the integrated density of the TATA-binding protein
band to determine the relative intensity. All wild-type, normoxic (WT) cell lines are indicated by checkered green bars, all cell lines exposed to 3-
days hypoxia (3HYP) are indicated by diagonal-lined pink bars, all cell lines exposed to 5-days of hypoxia (5HYP) are displayed by blue brick bars,
and the established MDR cell line (TR) is displayed as the speckled purple bar (the second bar on each graph). The cell lines are SKOV3 (SK),
MDA-MB-231 (231), and OVCAR5 (OV).
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Figure 5 Semi-quantitative Analysis of GLUT-1, HXK2, GAPDH, and LDH. Image J software was used to determine the relative intensity of
protein expression. The integrated density of each band was measured; this value was divided by the integrated density of the b-actin protein
band to determine the relative intensity. All wild-type, normoxic (WT) cell lines are indicated by checkered green bars, all cell lines exposed to 3-
days hypoxia (3HYP) are indicated by diagonal-lined pink bars, all cell lines exposed to 5-days of hypoxia (5HYP) are displayed by blue brick bars,
and the established MDR cell line (TR) is displayed as the speckled purple bar (the second bar on each graph). The cell lines are SKOV3 (SK),
MDA-MB-231 (231), OVCAR5 (OV), and MDA-MB-435 (435).
Figure 4 Semi-quantitative Analysis of P-gp, MRP-1, EGFR, and MITO-ATPase. Image J software was used to determine the relative intensity
of protein expression. The integrated density of each band was measured; this value was divided by the integrated density of the b-actin
protein band to determine the relative intensity. All wild-type, normoxic (WT) cell lines are indicated by checkered green bars, all cell lines
exposed to 3-days hypoxia (3HYP) are indicated by diagonal-lined pink bars, all cell lines exposed to 5-days of hypoxia (5HYP) are displayed by
blue brick bars, and the established MDR cell line (TR) is displayed as the speckled purple bar (the second bar on each graph). The cell lines are
SKOV3 (SK), MDA-MB-231 (231), OVCAR5 (OV), and MDA-MB-435 (435).
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Figure 6 Immunohistochemistry of 100 mm3 Normoxic and Hypoxic Tumor Xenografts. Tissue sections were probed with primary
antibodies against the protein of interest, then labeled with Alexa Fluor® 488 conjugated secondary antibodies (green). F-actin was stained with
Alexa Fluor® 568 phalloidin (red) and nuclei were stained with Hoechst 33342 (blue). These images represent protein expression in the tumor
core.
Figure 7 Immunohistochemistry of 250 mm3 Normoxic and Hypoxic Tumor Xenografts. Tissue sections were probed with primary
antibodies against the protein of interest, then labeled with Alexa Fluor® 488 conjugated secondary antibodies (green). F-actin was stained with
Alexa Fluor® 568 phalloidin (red) and nuclei were stained with Hoechst 33342 (blue). These images represent protein expression in the tumor
core.
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tumors grown to 500 mm3 (Figure 8). The only substan-
tial CD-31 expression was in the tumors derived from
normoxic cells grown to 500 mm3 (Figure 8).
Based on these distinctions, the 100 mm3 tumors
developed from hypoxic cells appear to have the most
MDR character that is clearly distinct from the tumors
developed from normoxic cells. As the tumor size
increased, the differences between the tumors derived
from normoxic and hypoxic cells decreased. There was
also a remarkable difference in the growth rate of
tumors developed from normoxic cells and those devel-
oped from hypoxic cells (Figure 9). As demonstrated in
Figure 9, the tumors developed from hypoxic cells
reached a 100 mm3 size within 3 weeks whereas it took
between 7-8 weeks for the tumors developed from nor-
moxic cells to reach this size. After reaching 100 mm3,
the differences in the rates of tumor growth decreased
as it took 2.5-3 months for both groups of tumors to
reach 500 mm3 (not shown).
To further examine the distinctions between the
100 mm3 tumors developed from normoxic cells and
those developed from hypoxic cells, IHC of the tumor
perimeter was examined (Figure 10 and Figure 11). (Fig-
ures 6, 7, and 8 represent the tumor cores). There is a
consistent difference between the expression of these
proteins in the core (Figure 6) and perimeter (Figure 10
and 11) of tumors developed from normoxic cells and
in those developed from hypoxic cells.
As with the tumor core, there is a low level of Pgp
expression in the perimeter of tumors developed from
normoxic cells. On the other hand, Pgp expression
seemed higher in the perimeter of tumors developed
from hypoxic cells than in the core. Hif-1a expression
was also higher in the perimeter of tumors derived from
hypoxic cells than in the core. Hif-1a expression was
low in the core of tumors derived from normoxic cells
and non-detectable in the perimeter. EGFR expression
appeared to be decreased in the perimeter of tumors
grown from normoxic cells relative to the core. Conver-
sely, EGFR expression maintained high expression levels
in both the perimeter and core of tumors developed
from hypoxic cells. There was no apparent difference in
CD-31 expression between the perimeter and core of
both groups of tumors as all sections had either very
low or non-detectable levels of this protein. The expres-
sion of hexokinase 2 was consistent between the tumor
perimeter and tumor core for both groups of tumors;
with low and localized levels in the tumor sections
developed from normoxic cells and highly profuse
expression in the tumor sections developed from
Figure 8 Immunohistochemistry of 500 mm3 Normoxic and Hypoxic Tumor Xenografts. Tissue sections were probed with primary
antibodies against the protein of interest, then labeled with Alexa Fluor® 488 conjugated secondary antibodies (green). F-actin was stained with
Alexa Fluor® 568 phalloidin (red) and nuclei were stained with Hoechst 33342 (blue). These images represent protein expression in the tumor
core.
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hypoxic cells. GLUT-1 expression was high in both the
tumor perimeter and core of tumor sections derived
from hypoxic cells whereas the perimeter of tumors
developed from normoxic cells had higher and more
profuse expression than the core where expression was
very localized.
Collectively, the expression of Pgp and Hif-1a was ele-
vated in the perimeter of tumors established from
hypoxic cells relative to the core while the perimeter of
tumors established from normoxic cells had lower
expression of EGFR and higher expression of GLUT-1
relative to the tumor core. Based on the differences in
Figure 9 Normoxic and Hypoxic tumor Growth; Time to Achieve 100 mm3. Normoxic and Hypoxic tumor xenografts were established in
the mammary fat pad of female nude mice and tumor growth was monitored until 100 mm3 tumors were achieved. The tumor size was
measured every other day using Vernier calipers in two dimensions. Individual tumor volumes were calculated using the formula volume =
[length × (width)2]/2 where the length was the longest diameter and the width was the shortest diameter perpendicular to length. For each
group, n = 6. Each data point represents the mean ± SD.
Figure 10 Immunohistochemistry of 100 mm3 Normoxic Tumor
Perimeter. Tissue sections were probed with primary antibodies
against the protein of interest, then labeled with Alexa Fluor® 488
conjugated secondary antibodies (green). F-actin was stained with
Alexa Fluor® 568 phalloidin (red) and nuclei were stained with
Hoechst 33342 (blue). These images represent protein expression in
the tumor perimeter.
Figure 11 Immunohistochemistry of 100 mm3 Hypoxic Tumor
Perimeter. Tissue sections were probed with primary antibodies
against the protein of interest, then labeled with Alexa Fluor® 488
conjugated secondary antibodies (green). F-actin was stained with
Alexa Fluor® 568 phalloidin (red) and nuclei were stained with
Hoechst 33342 (blue). These images represent protein expression in
the tumor perimeter.
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protein expression between the groups of tumors in
both the perimeter and the core, as well as the differ-
ences in the early growth rates of the tumors, it was
inferred that 100 mm3 tumors developed from hypoxic
cells have more MDR character than 100 mm3 tumors
developed from normoxic cells. These tumors estab-
lished from hypoxic pre-conditioned cells may be a use-
ful model for the study of MDR breast cancer.
4. Discussion
4.1. Inclusion of MDA-MB-435 Cells
Although the lack of EGFR expression is well character-
ized in the MDA-MB-435 cell line, the actual origin of
this cell line is controversial. Recent studies suggest that
this cell line has been incorrectly characterized as a
breast carcinoma cell line and is more likely derived
from melanocytes [48]. Regardless of the controversy,
this cell line was included in these experiments as a
negative control for EGFR-expression.
4.2. Protein Changes in Response to Hypoxia
Expression of active HIF-1a in the nucleus of cells
grown under normoxic conditions is most likely a
cellular response to previously mentioned oxygen-
independent factors (such as EGFR or phosphatidylino-
sitol 3-kinase), or a response to stress factors and
homeostatic dis-regulation that is characteristic of can-
cer. For example, von Hippel-Lindau is a tumor sup-
pressor protein that contributes to the transformation of
certain types of cancer, such as renal cell carcinoma, via
negative regulation of HIF-1a [22,49,50].
An interesting distinction between HIF-1a and HIF-
2a expression was that HIF-1a expression was apparent
in all cell lines whereas HIF-2a appeared only to be
induced by hypoxia. This suggests that hypoxia induces
the nuclear translocation of HIF-2a, yet oxygen-inde-
pendent factors and conditions of cell stress (such as
those in the MDR cells) are not sufficient to induce this
translocation. Based on these results, it is likely that
both HIF-1a and HIF-2a isoforms are central to the
development of MDR but induction of each isoform
occurs in response to different cellular and environmen-
tal factors. This could result in different MDR pheno-
types as the targets of each isoform vary.
Increased glycolysis in the absence and presence of
oxygen (the Pasteur and Warburg effects) are important
hallmarks of cancer. The Warburg Effect is associated
with aggressive, MDR cancer [4,21,29,51,52]. Glycolysis
is another thread that connects MDR and hypoxia;
increased glycolysis is characteristic of MDR cancer and
most glycolytic enzymes are HIF-1a targets that are
transcriptionally activated in response to hypoxia
[21,22,24,26,28,29,32-36]. Activation of HIF-1a by glyco-
lytic proteins has also been demonstrated, suggesting a
feedback loop between the glycolytic and HIF-1a path-
ways [34]. However, as these results demonstrate, cancer
cells do not have a universal response to hypoxia. The
Pasteur effect appears to be duration dependent in the
SKOV3 and MDA-MB-231 cells yet the OVCAR5 cells
seem resistant to hypoxia induced glycolysis. The feed-
back loop between hypoxia and glycolysis may be more
relevant in certain subsets of cancer and non-existent in
other types of cancer.
The hypoxic transformation, phenotype changes in
response to hypoxia, do not appear to be consistent
among the cell lines in regard to mitochondrial ATP
synthase expression. The hypoxic transformation of
MDA-MB-231 cells may lead to such an excessive
demand for energy that the expression of both glycolytic
and OXPHOS enzymes is increased as a survival
response. Hypoxic transformation of SKOV3 cells may
depress the cell cycle, decreasing the energetic demands
of cell, leading to decreased OXPHOS. It is possible also
that these differences in ATP synthase expression corre-
late more to mitochondrial differences between the cell
lines than to a hypoxic response; a more complete pro-
filing of mitochondrial enzymes would be necessary to
determine this.
Collectively, the protein analysis results indicate that
each cell line has a cell-specific threshold for hypoxic
transformation. The MDA-MB-231 breast cancer cells
underwent the most significant hypoxic transformation
with an increase in all proteins examined (HIF tran-
scription factors, HIF targets, MDR proteins, and glyco-
lytic proteins). Although hypoxia induced MDR
character and glycolysis in the SKOV3 ovarian cancer
cells, the transformation required more chronic hypoxic
exposure (five days). Five days of hypoxia was not suffi-
cient in transforming the OVCAR5 cells. These results
demonstrate the diverse proteomic responses of the dif-
ferent cell lines. Although the OVCAR5 cells express
GLUT-1, these cells appear to have less overall glycoly-
tic character than the other cells examined (lower
HXK2, GAPDH, and LDH) and appear to be resistant
to hypoxia induced MDR and hypoxia induced glycoly-
sis. These cells may require additional stimuli for
hypoxic transformation or may have a genetic resistance
to the hypoxia induced HIF cascade. These results also
suggest that the distinction between the Pasteur and
Warburg effects may not be universal as the degree of
hypoxia (percent oxygen depletion) is critical in deter-
mining the cell specific response. The Pasteur effect is a
suppression of glycolysis in the presence of oxygen
whereas the Warburg effect is glycolysis in the presence
of oxygen. The current results reveal that there are cell-
specific thresholds for the Pasteur effect; additional and
more detailed studies would likely reveal a critical oxy-
gen concentration for each cell type where the Pasteur
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and Warburg effects are difficult to distinguish. Perhaps
more significant than the isolated study of the Pasteur
and Warburg effects is the unfolding relationship
between HIF and glycolysis as this relationship is pre-
sent in cancer cells under both normoxic and hypoxic
conditions [34,35,39-41].
Although unlikely, as cells were plated at a low den-
sity, it is important to note that as the oxygen consump-
tion rate was not measured in these studies, it is
possible that peri-cellular oxygen depletion in the nor-
moxic cell population could create hypoxic conditions,
which would make the expression profile of normoxic
cells more similar to hypoxic cells.
4.3. Orthotopic Model Development
An important finding of this study was that the protein
expression profile of both tumor xenografts developed
from normoxic cells and xenografts developed from
hypoxic cells changed as the tumor size increased. The
100 mm3 xenografts established from hypoxic cells were
clearly distinguishable from the 100 mm3 xenografts
established from normoxic cells, but these differences
decreased as the tumor size increased.
The elevated level of HIF-1a in the perimeter of
100 mm3 tumors developed from hypoxic cells is less
likely due to lower oxygen relative to the core (as it is
probable that the perimeter is more vascularized) and
more likely due to oxygen-independent factors, cell
stressors, oncogenes, and tumor suppressors that char-
acterize cancer and up-regulate HIF. The elevated level
of Pgp in the perimeter of tumors (100 mm3) developed
from hypoxic cells relative to the core may be due to
the increased expression of HIF, as Pgp is transcription-
ally activated by HIF, or may be a spatial response to
microenvironmental factors as it is these cells in the
perimeter of a tumor that are most likely to have the
first contact with therapeutic agents. The decreased
EGFR expression in the perimeter of tumors established
from normoxic cells relative to the core may be because
the core of the tumor is more starved for growth factor
activation, and hence increases EGFR in an attempt to
be more susceptible to growth factors. Alternatively, the
higher level of GLUT-1 in the perimeter of tumors
derived from normoxic cells relative to the core may be
due to a positive feedback loop with available glucose.
Collectively, the IHC analysis of the tumor cores and
perimeters (as well as the growth curves) illustrate the
more pronounced MDR character of the 100 mm3
tumors established from hypoxic cells relative to 100
mm3 tumors developed from normoxic cells.
Hypoxic pre-conditioning of the tumor cells may
result in more aggressive, MDR xenografts due to the
upregulation of HIF and subsequent activation of HIF
targets (such as growth factor receptors, MDR efflux
pumps, and glycolytic proteins); this was demonstrated
by the western blot data in this study. This activation
may provide these cells with an initial growth advantage
during xenografting establishment, as demonstrated by
the tumor growth curves. The hypoxic pre-conditioning
may activate the HIF cascade and MDR character in the
cells, enabling initial, rapid growth of the xenografted
cells before the establishment of profuse tumor vascula-
ture, whereas the xenografts established from normoxic
cells may not exhibit aggressive phenotypes until the
angiogenic process is complete. This correlates with the
expression of CD-31 (angiogenic marker), as the only
substantial CD-31 expression was seen in the tumor sec-
tions of 500 mm3 xenografts established from normoxic
cells. Expression of CD-31 in the 500 mm3 xenografts
established from normoxic cells coincided with an
increase in expression of HIF and all down-stream tar-
gets of HIF associated with MDR, similar to the expres-
sion of HIF, Pgp, EGFR, HXK2, and GLUT-1 in the the
500 mm3 xenografts established from hypoxic cells.
Angiogenesis has long been associated with primary
tumor growth and metastasis, but recent evaluations of
anti-angiogenic therapy reveal that anti-angiogenic
therapies can actually increase metastasis and invasion
[53-55]. These studies suggest hypoxic tolerance as a
possible mechanism for this increased invasion and
metastasis [54]. Hypoxic pre-conditioning may elicit a
similar cellular response as is seen with anti-angiogenic
therapy, resulting in aggressive disease.
Exploiting the Pasteur effect by using hypoxic pre-
conditioning is a useful technique for creating MDR
tumor xenografts. We have developed an animal model
of MDR breast cancer using hypoxic MDA-MB-231
cells. Although this approach of using hypoxic cells for
xenografts will not be effective for every type of cancer,
as demonstrated with the OVCAR5 cells, it will
undoubtedly be applicable to other cancer cell lines.
This approach could dramatically expand the repertoire
of MDR cancer models and could be used to study the
Pasteur and Warburg effects in orthotopic models.
Using this method of hypoxic pre-conditioning could
enable the rapid in vivo study of many different types of
MDR cancer, which would not otherwise be possible.
5. Conclusions
Hypoxia alone is sufficient in transforming normal
cancer cells into MDR cancer. Hypoxia also induces gly-
colysis in some cancer cells (the Pasteur effect) further
increasing their survival advantage. Increased expression
of MDR and glycolytic proteins in response to hypoxia
is cell-type and duration dependent.
An animal model was developed for orthoptopic MDR
breast cancer using hypoxic MDA-MB-231 cells in
female athymic mice. Immunohistochemistry of the
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tumor model demonstrated that the tumors derived
from hypoxic cells had higher MDR character relative to
tumors derived from normoxic cells. This character was
maintained in the tumor perimeter and core. The
tumors established from hypoxic cells also demonstrated
more aggressive growth relative to tumors established
from normoxic cells. This method of hypoxic pre-condi-
tioning could be used to develop a multitude of orthoto-
pic animal models of MDR cancer, further expanding
the study of the disease.
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